معرفی
Brad Jones is an Associate Professor at Weill Cornell Medicine in the Department of Microbiology and Immunology with a cross-appointment in the Division of Infectious Diseases. He leads the Laboratory of Antiviral Cellular Immunity (Jones Laboratory) focused on HIV cure research.
Dr. Jones received his PhD in Immunology from the University of Toronto before completing a post-doctoral fellowship at the Ragon Institute of MGH, MIT, and Harvard in 2012. His educational background includes a B.Sc. from Simon Fraser University (Canada) in 2004.
Dr. Jones' research focuses on understanding the relationships between HIV and the human immune system, particularly cytotoxic T cells and natural killer cells, with the ultimate goal of developing a cure. His laboratory explores multidisciplinary approaches including enhancing immune cell function through genetic engineering, identifying latency reversal agents, and developing strategies to target T cells against non-escaped viral epitopes. Current projects include identifying mechanisms of immune clearance resistance, studying how HIV integration sites influence viral persistence, optimizing T-cell vaccine strategies, and conducting clinical trials of immunotherapeutic agents.
Analysis of Dr. Jones' recent publications reveals a strong emphasis on HIV reservoir characterization, immune evasion mechanisms, and novel therapeutic approaches. His work spans basic virology, translational research, and clinical applications, with particular focus on understanding why current therapies cannot eliminate HIV and how to overcome these barriers.
- Principal Investigator of the $28M Research Enterprise to Advance a Cure for HIV (REACH)
- Steering Committee Member – Global Scientific Strategy for an HIV Cure (International AIDS Society)
- Scientific Advisory Board Member – French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Dr. Jones serves as Principal Investigator for multiple NIH-funded research projects totaling over $28 million, including the REACH Collaboratory. His research program involves extensive collaboration with clinical and basic science investigators across multiple institutions. He also consults for VIIV Healthcare and maintains an active laboratory focused on developing novel approaches to eliminate HIV reservoirs.
The Jones Laboratory utilizes a range of approaches from basic molecular virology to preclinical models and clinical trials to advance HIV cure research. The lab has developed innovative models including participant-derived xenograft models to study HIV persistence and evaluate immunotherapies.
